Guizhou Chitianhua Co.,Ltd. (GUIZHOU CHITIANHUA CO LTD) aksje
600227.SS
GUIZHOU CHITIANHUA CO LTD
Market Cap
$5,235,055,616
Om Guizhou Chitianhua Co.,Ltd. (GUIZHOU CHITIANHUA CO LTD) aksje
Guizhou Chitianhua Co.,Ltd. engages in the chemical and pharmaceutical businesses in China. The company offers urea fertilizers; synthetic ammonia and ammonium sulfate; and sulfuric acid, industrial nitrogen, industrial ammonia, and industrial hydrogen, as well as basic chemical products and their deep-processed and by-products. It also produces and sells pharmaceuticals; medical equipment; and drugs for diabetes, cardiovascular, dermatology, gynecological, digestive system, endocrine, and psychotropic diseases. In addition, the company engages in the production of Chinese and western patent medicines; class II clinical laboratory analysis instruments; and sanitary products, as well as sales of self-produced products. Further, it is involved in the manufacture and sales of special and daily chemical products; provision of technical development, consultation, exchanges, and services; technology transfer and promotion; coal washing; sales of coal products; import and export of technology and goods; motor vehicle repair and maintenance; health care products; retailing of prepackaged foods; software technology development and services; data processing services; health consultation; production and sales of cosmetics; planting of Chinese herbal medicines; sales and storage services of cells; research on stem cell biotechnology and gene technology; production of biological products; investment in coal construction projects; and sales of industrial and mining products, mining equipment and spare parts. Guizhou Chitianhua Co.,Ltd. was formerly known as Guizhou Salvage Pharmaceutical Co.,Ltd. and changed its name to Guizhou Chitianhua Co.,Ltd. in May 2023. The company was founded in 1998 and is based in Guiyang, China.
Selskapsinformasjon
550008 Guiyang, China
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.